ReviewVaccine2017
Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology.
Review in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.Nature medicine · 2021Trial
- Immunogenicity of a bivalent recombinant adenovirus expressing VP1 proteins of bovine norovirus and bovine nebovirus in mice and calves.BMC microbiology · 2025Article
- Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster.Human vaccines & immunotherapeutics · 2023Article
- Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use.Vaccines · 2023Review
- Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein.Antibody therapeutics · 2022Article
- Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.The Lancet. Microbe · 2022Article
- Brief exposure of skin to near-infrared laser augments early vaccine responses.Nanophotonics (Berlin, Germany) · 2021Article
- A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.European journal of immunology · 2021Article
- Prioritizing investments in rapid response vaccine technologies for emerging infections: A portfolio decision analysis.PloS one · 2021Article
- Emerging Concepts and Technologies in Vaccine Development.Frontiers in immunology · 2020Review
- Article
- Emerging viruses and current strategies for vaccine intervention.Clinical and experimental immunology · 2019Review
- CEPI: Driving Progress Toward Epidemic Preparedness and Response.Epidemiologic reviews · 2019Review
- Review
- Pharmacotherapy of Lower Respiratory Tract Infections in Elderly-Focused on Antibiotics.Frontiers in pharmacology · 2019Review
- An updated roadmap for MERS-CoV research and product development: focus on diagnostics.BMJ global health · 2019Article
- Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models.Journal of thoracic disease · 2018Review
- Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic.Nature immunology · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Despite the fact that there had been multiple small outbreaks of Ebola Virus Disease, when a large outbreak occurred in 2014 there were no vaccines or drugs available for use. Clinical development of multiple candidate vaccines was then initiated in parallel with attempts to contain the outbreak but only one vaccine was eventually tested in a phase III trial. In order to be better prepared for future outbreaks of known human pathogens, platform technologies to accelerate vaccine development should be employed, allowing vaccine developers to take advantage of detailed knowledge of the vaccine platform and facilitating rapid progress to clinical trials and eventually to vaccine stockpiles. This review gives an example of one such vaccine platform, replication-deficient simian adenoviruses, and describes progress in human and livestock vaccine development for three outbreak pathogens, Ebola virus, Rift Valley Fever Virus and Middle East Respiratory Syndrome Coronavirus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.